For research use only. Not for use in humans.

Bemarituzumab (Anti-FGFR2 / CD332)

Synonyms: BBDS, BEK

Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD.

Bemarituzumab (Anti-FGFR2 / CD332)

Click to purchase the isotype control of Bemarituzumab (Anti-FGFR2 / CD332)

Quality Control

Batch: A249701 Purity: 99% Protein concentration: 3.55mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Name Citation FGFR FGFR1 FGFR2 FGFR3 FGFR4 Others
PD173074 125 VEGFR2
Dovitinib (TKI-258) 53 FLT3,c-Kit,VEGFR3/FLT4
AZD4547 (Fexagratinib) 147 KDR
Danusertib (PHA-739358) 46 Aurora A,Abl,TrkA
Brivanib (BMS-540215) 15 VEGFR2,Flk1,VEGFR1
ENMD-2076 13 FLT3,RET,Aurora A
MK-2461 5 c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
Brivanib Alaninate (BMS-582664) 2 VEGFR2,Flk1,VEGFR1
Tyrphostin AG 1296 14 PDGFR,c-Kit (Swiss 3T3)
SSR128129E 10
Irpagratinib 0
R1530 0 VEGFR2
FIIN-3 0
Lucitanib (E3810) hydrochloride 1 VEGFR1,VEGFR3,VEGFR2
Rogaratinib 0
Sulfatinib 2 VEGFR3,VEGFR1,CSF1R
ODM-203 0 VEGFR3,VEGFR2,VEGFR1
Futibatinib (TAS-120) 17
ASP5878 3
Derazantinib 4 RET,DDR2,PDGFRβ
H3B-6527 15
Roblitinib (FGF401) 6
PRN1371 2 CSF1R
PD-166866 15
Fisogatinib (BLU-554) 12
S49076 1 Met,Mer,Axl
NSC12 3 FGF3,FGF8b,FGF22
ON123300 4 CDK4/CyclinD1,ARK5,RET
SU 5402 25 VEGFR2,PDGFRβ
BLU9931 21
FIIN-2 5
Dovitinib (TKI258) Lactate monohydrate 31 FLT3,c-Kit,VEGFR3/FLT4
Zoligratinib (Debio-1347) 12
LY2874455 15 VEGFR2
Ferulic Acid 6
Resigratinib 0
Lirafugratinib (RLY-4008) 0
Masitinib mesylate 2 FAK,human recombinant c-Kit,LynB
BO-264 0 TACC3
SKLB 610 2 PDGFR,VEGFR2
Alofanib (RPT835) 6
Gambogenic acid 5 EZH2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD.

Product Details

CAS No. 1952272-74-0
Molecular Weight 145.24 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07146919 WITHDRAWN Drug: Bemarituzumab|Drug: Bevacizumab Endometrial Carcinoma; Ovarian Cancer; Cervix Cancer Centre Leon Berard 2025-10-15 PHASE1; PHASE2
NCT07470840 NOT_YET_RECRUITING Drug: Anlotinib|Drug: Bemarituzumab Locally Advanced or Metastatic Renal Cell Carcinoma Fujian Cancer Hospital 2027-02-01 PHASE2
NCT06978062 NOT_YET_RECRUITING Drug: Bemarituzumab|Drug: FLOT GastroEsophageal Cancer European Organisation for Research and Treatment of Cancer - EORTC 2026-02-20 PHASE1
NCT06680622 ACTIVE_NOT_RECRUITING Drug: bemarituzumab, paclitaxel, ramucirumab|Drug: bemarituz Metastatic Gastro-esophageal Adenocarcinoma Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 2025-03-03 PHASE2
NCT06897579 TERMINATED Drug: Carboplatin for injection/cisplatin for injection + et Extensive Stage Small Cell Lung Cancer Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 2025-04-07 PHASE2
NCT05325866 TERMINATED Drug: Bemarituzumab Solid Tumors Amgen 2022-09-23 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2026-04-23)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.